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1. Introduction 
Intradialytic hypotension (IDH) is the most common complication of hemodialysis (HD), 
occurring in up to 20 to 33% of sessions (Daugirdas, 2001). IDH is responsible for various 
minor symptoms (nausea, vomiting, muscle cramps, dizziness, and fatigue) during dialysis, 
but is also associated with more severe adverse events such as myocardial infarction (Burton 
et al., 2009) and cerebral ischemia (Mizumasa et al., 2004). Moreover, as a result of frequent 
interruption of sessions and repetitive administration of intravenous fluids, underdialysis 
and inability to reach dry weight, with subsequent chronic overhydration, can follow.  
Traditionally, HD prescriptions are based on clinical evaluation and laboratory 
measurements, and are re-evaluated periodically or when an adverse event, such as 
hypotension, commands it. The drawback of this prescription is that it relies on previous 
observations, with the assumption that the same will hold true for the next sessions. Hence, 
it implies discomfort for the patients, as the actions to remediate to IDH, for example, by 
stopping ultrafiltration (UF) or adjusting dry weight, are taken on an a posteriori basis 
(Locatelli et al., 2005). 
In an attempt to prevent IDH, technological advances have made possible the detection of 
subclinical predictors of hemodynamic instability, for example relative blood volume 
variations. With repetitive measurement of such specific parameters during HD (Mercadal 
& Petitclerc, 2009), actions can be implemented to correct the monitored parameter toward a 
desired target, with the aim of preventing overt IDH. When this action is automatic and 
regulated by a closed feedback loop, it is called biofeedback.  
In this chapter, we will review some of the physiological basis of IDH and blood volume 
reduction during HD, and we will examine the technical aspects of the various devices used 
to adjust blood volume during dialysis, with special emphasis on biofeedback systems. 
Finally, we will study the literature published on the effects of automated blood volume 
regulation devices on the occurrence of hypotensive episodes, volume overload control, 
hypertension management and quality of life in chronic HD patients.   
2. Intradialytic hypotension 
The causes of IDH are multifactorial. On one side, a number of patient-related conditions 
can promote blood pressure (BP) fall during HD: age, comorbidities such as diabetes and 
cardiomyopathy, anemia, large interdialytic weight gain (IDWG), use of anti-hypertensive 
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medication, etc. On the other hand, factors associated with the dialysis prescription itself can 
also contribute to hemodynamic instability: short HD sessions, high ultrafiltration rate, high 
dialysate temperature, low dialysate sodium concentration, inflammation caused by 
membrane activation, etc. As a consequence, various interventions aimed at modulating 
these parameters have been proposed to ameliorate the vascular tolerance to ultrafiltration 
(UF), but with variable efficacy and limited benefits. 
On a physiological basis, IDH can be viewed as the inability of the cardio-vascular system to 
respond adequately to the reduction of blood volume. Cardio-vascular reactivity involves 
reflex activation of the sympathetic system, with appropriate tachycardia and arterial and 
venous vasoconstriction in response to cardiac underfilling and hypovolemia. These 
compensatory mechanisms are altered in some patients, which put them at risk of 
developing IDH. However, these are difficult to assess and to modify. Comprehensive study 
of blood volume regulation during HD can help understand IDH susceptibility of 
individual patients. 
3. Blood volume regulation 
3.1 Concept of plasma refilling  
Blood volume is dependent on two main factors: plasma refilling capacity and UF rate. 
During HD, fluid is removed directly from the intravascular compartment. Total body water 
(TBW), which is about 60% of body weight (BW), is distributed in part in the intracellular 
(40% BW) and in part in the extracellular (20% BW) compartments. The latter is further 
subdivided in the interstitial (15% BW) and the intravascular (5% BW) spaces. Thus, only 8% 
of the TBW is readily available for UF. Therefore, in order to remove a substantial amount of 
fluid during a short period of time, the vascular compartment needs to be continuously 
refilled from the interstitial space. 
Plasma refill is mostly driven by hydrostatic and oncotic forces. During the first part of a 
HD session, the vascular oncotic pressure raises and the hydrostatic pressure lessens as a 
result of progressive UF.  Pressure gradients thus created drive the water back into the 
vascular space until a new equilibrium is reached. As UF and water withdrawal from the 
intravascular space continue, the new disequilibrium thereby generated has to be once again 
balanced, and so on until the end of the session (Santoro et al., 1996). Several factors can 
influence rate of plasma refilling by acting on these forces: hydration status, plasma 
osmolality, and plasma protein concentration. Patient’s proper refilling capacity, which is 
not measurable as a parameter, also has an effect on the rate at which water moves back in 
the blood vessels. Overall, IDH is generated when the imbalance between UF rate and 
plasma refilling capacity cannot be surpassed by cardio-vascular compensatory reflexes.  
3.2 Relative blood volume measurement 
Cardio-vascular reactivity and plasma refilling capacity of each patient, albeit central in the 
pathogenesis of IDH development, are difficult to assess and therefore are not convenient as 
monitoring tools. Direct measurement of blood volume is feasible, classically using dilution 
of radioactively labelled blood elements (such as 131I albumin or 51Cr red blood cells), but it 
implies serial blood tests and radiation, and so is clearly impractical for the repetitive 
assessment of blood volume. One way to circumvent this problem is to measure blood 
volume change during HD which, as a surrogate marker of vascular refilling, can be 
estimated using bedside devices.  
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Relative blood volume (RBV) is the term used to describe « the blood volume at any time as 
a percentage of the blood volume at the commencement of treatment » (Nesrallah et al., 
2008). Most of the non-invasive devices extrapolate the RBV change from the variation of the 
hemoconcentration of a blood element. The basic premise of this calculation is that if the 
blood component remains constant throughout the HD session (i.e., the numerator), the 
variation of its concentration is necessarily due to the change in the blood volume (i.e., the 
denominator). The various devices available vary in the blood element they measure (i.e., 
red blood cells, hematocrit, total protein concentration) and in the method used to measure 
it (i.e., optical absorbance, ultrasound, etc.). 
One caveat of these techniques is that they are based on the assumption that uniform mixing 
of the measured blood element and plasma occurs throughout the whole circulation 
(Dasselaar et al., 2007a). Venous (or systemic) hematocrit (Hctsys) is usually higher than 
whole-body hematocrit (Hctw), due to the dynamic reduction of hematocrit in the 
microcirculation during blood flow through capillaries and venules. This is expressed as the 
F-cell ratio, Hctw/Hctsys. However, during UF, it was shown that the F-cell ratio rises as a 
result of the compliance of the microcirculation and fluid transfer to the macrocirculation. 
Therefore, the equations on which the inference of the blood volume change during HD is 
based may not be always valid (Mitra et al., 2004).  
In a study from Dasselaar et al. (2007a), the blood volume reduction estimated by three 
commonly used devices (Crit-line®, Hemoscan® and BVM®, see below) was compared to a 
standard laboratory-derived Hb relative blood volume measurement during two HD 
sessions. It was shown that all three devices systematically overestimate the RBV reduction 
at modest RBV change, and underestimate the real fall in blood volume at higher RBV 
decline.  
In addition, RBV monitoring also assumes that red blood cell mass or plasma protein 
density remains constant throughout the length of the session, which may not be true if 
hemolysis or blood leak happens, or when a blood transfusion is given.  
3.3 Relation between relative blood volume and intradialytic hypotension 
While hypovolemia is clearly a major determinant in the pathogenesis of IDH, the link 
between blood volume reduction and appearance of arterial hypotension is still a matter of 
debate. Recent studies have been unable to find a linear relationship between RBV and 
blood pressure, and a specific threshold to which hypotension will certainly occur does not 
seem to exist, even in an individual patient. This is probably because of variations, for each 
treatment, in the patient’s ability to activate cardio-vascular compensatory mechanisms, in 
order to offset BP reductions induced by a wide range of hypovolemic states.  
In fact, in many trials where blood volume (BV) biofeedback was effective in reducing the 
occurrence of IDH, there was no difference in the final RBV reached by either the standard 
treatment or the BV-controlled treatment. According to some authors, it is possible that RBV 
reduction per se is not the main risk factor for development of IDH. Rather, the excessive 
fluctuations of BV and the form of the RBV slope during HD may contribute more to 
hemodynamic instability (Andrulli et al., 2002). Indeed, the slope of the RBV curve with BV 
regulation device is different from that produced by standard HD (Franssen et al, 2006). The 
initial phase is usually steeper (meaning higher UF rate), which is rendered possible and 
tolerable because of higher initial interstitial pressures and better plasma refilling rate. The 
second phase is characterized by a reduced UF rate, which in turn make the RBV more 
stable and the patient less prone to IDH in this vulnerable period.   
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4. Biofeedback system 
While monitoring may help to understand how BV is regulated during UF in an individual 
patient, the HD prescription often remains empirical. The hemodynamic stability during the 
previous HD sessions dictates the delivered parameters of the next HD treatments. Dialytic 
parameters such as UF rate and dialysate sodium concentration are usually set at the start of 
the HD session, and remain fixed throughout the treatment, with the assumption that they 
continue to be adequate for the whole treatment duration. However, this is not taking into 
account that patients may undergo physiologic variations during HD, and that fixed 
parameters, creating labile gradients, may not always be appropriate and may promote 
IDH. In fact, the standard HD prescription lacks a rapid retroactive response in case of 
variation of the monitored parameter, as the action to bring it back towards the desired 
value are taken manually (by the operator, a nurse or physician) or semi-automatically 
(authorized by the operator) (Locatelli et al., 2005), thus implying a certain lag of time that 
may be deleterious if IDH is to be prevented. 
The method used to traditionally prescribe HD parameters is far from how the kidneys 
really behave to maintain internal homeostasis, keeping biologic variables in very tight 
ranges through instantaneous adjustments in response to precise negative or positive 
feedback loops. To try to get closer to what would be called « physiological dialysis », 
technological advances of the last decades have conducted to the development of 
sophisticated softwares that allow automated biofeedback. The concept of biofeedback is 
based on repetitive on-line measurements of the patient’s biochemical parameters with 
biosensors, which are then constantly analysed by an automatic controller as being within 
the target values pre-set by the operator, or not. If the measured parameter is within the 
desired values considered safe, the treatment continues unchanged. If not, an action to bring 
it back towards the aimed values is immediately and automatically undertaken through the 
effectors, in a closed-loop that insures the stability of the monitored parameter.  
The theoretical advantage of such devices is that they not only rapidly detect physiological 
abnormalities which may predict hemodynamic instability (blood volume reduction for 
example), but they automatically adjust one or more dialytic parameters to correct the 
situation.  This obviates the need to perform manual changes by the operator and, at the same 
time, avoids the time lag before the action is undertaken. By modulating on-line some of the 
delivered dialysis parameter, these devices also address the physiological variations occurring 
during HD (and the variability of the patient’s parameters from session to session), and thus 
provide more physiological dialysis, which may be more suited to prevent IDH. 
At the present time, biofeedback systems are available for different parameters: relative 
blood volume, thermal energy balance, plasmatic conductivity, to which arterial pressure 
feedback using fuzzy logic control can be added. These devices are described here, with 
emphasis on blood volume biofeedback. 
5. Blood volume biofeedback 
Currently, only two commercially blood volume biofeedback devices are available: the 
Hemocontrol® (Gambro) and the BVM® (Fresenius) systems. Although both monitor 
change in relative blood volume during HD, they use different technologies and different 
integration systems. They are reviewed here.  
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5.1 Hemocontrol® system 
The Hemocontrol® blood volume management system was first designed by Santoro and 
colleagues (Santoro et al., 1994) and afterwards modified in collaboration with the Hospal-
Gambro research group. It is available on the Integra® and Artis® machines (with a few 
updates on the latter).  
This biofeedback system is based on an automatic multi-input multi-output controller 
(MIMO) capable of integrating a multitude of signals and to modulate controlled variables 
to force the blood volume reduction along a pre-defined trajectory towards a pre-defined 
target of blood volume reduction (Locatelli et al., 2005). This results in a smoother and more 
gradual decline of relative blood volume, limiting the irregularity of BV variation that was 
shown to be predictive of IDH (Andrulli et al., 2002). 
Basically, the monitored parameters are the actual UF (or weight loss), the actual dialysate 
sodium (or conductivity) and the actual blood volume change. The differences between the 
target values of the same three parameters (that is: desired UF, desired dialysate sodium (or 
equivalent conductivity) and desired final blood volume change) and the actual parameters 
serve as inputs to the MIMO controller. At any moment, the actual BV curve is plotted 
against the pre-determined BV trajectory and, should it deviate the least, automatic 
modulation of the UF rate and dialysate sodium (or conductivity) allows smooth redirection 
to the « ideal » curve (figures 1 and 2).  
The blood volume change during dialysis is monitored using an optical sensor located in the 
arterial line that measures on-line hemoglobin (Hb) concentration by optical absorbance, 
according to Lambert-Beer law. The law states that Hb is a function of monochromatic light 
absorbance. Provided that the amount of Hb does not change, the blood volume variation 
from the start of the session can be inferred from the change in Hb concentration.  
 
 
 
 
 
 
Fig. 1. Hemocontrol® biofeedback system (from Gambro). 
The three targets prescribed by the physician (total UF, final dialysate sodium, and final BV 
reduction) are computed in the Hemocontrol® software and are compared to the actual 
same parameters (UF, dialysate sodium, and RBV) on a continuous basis during HD. The 
controller can modulate the UF rate and dialysate sodium in order to bring the actual 
parameters back on the pre-determined trajectory of the RBV curve.   
www.intechopen.com
 
Progress in Hemodialysis – From Emergent Biotechnology to Clinical Practice 
 
32
 
Fig. 2. Optimal trajectory of Relative blood volume (RBV) reduction during HD with 
Hemocontrol® (from Gambro). 
The Hemocontrol® software designs the ideal RBV reduction curve, for each patient at each 
session, based on both initial and target parameters. Upper and lower tolerance limits are set 
to ensure safety. UF rate and dialysate sodium vary continuously during HD to keep the 
actual curve parallel to the optimal trajectory.  
In practical terms, several parameters need to be set. Before the first use, data on the 
patient’s sex, age, height and weight are needed to calculate total body water with any of the 
proposed formula. Treatment duration is also determined before the beginning of the 
treatment. Then, the three main targets need to be specified: 
1. Total body weight loss or total UF (for water balance), based on clinical evaluation of 
dry weight;  
2. Final sodium or equivalent dialysate conductivity. Conductivity refers to the electrical 
conducting property of the dialysis solution given by the dissociation of inorganic salts into 
charged ions. Since sodium is the principal ion in solution, conductivity is used as a 
surrogate for sodium concentration. For simplification purpose, conductivity was replaced 
by sodium concentration in the recent devices. Equivalent conductivity represents the 
dialysate conductivity that produces the same sodium balance at the end of a BV regulated 
session as a HD session with constant dialysate conductivity (Franssen et al., 2005); 
3. Relative BV change to be reached at the end of HD which is individually determined for 
each patient on the basis of anterior sessions. A short observation period 
(approximately two weeks) is usually required to analyse each patient’s BV curve 
morphology and to determine their respective BV/UF ratio. This ratio represents the 
%BV per each kilogram of UF fluid, and indirectly reflects the individual patient 
refilling plasma capacity. Depending on this ratio, and on the total UF prescribed for 
each dialysis, the final %BV can be adjusted. 
Of note, these three targets may sometimes be in conflict with each other, for example when 
large UF is prescribed for a patient with low plasma refilling rate (i.e. a high BV/UF ratio). 
The closed feedback loop system has then to reach the best compromise between the various 
targets and produce the most appropriate BV curve for this patient during that specific 
session.  
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Because of safety concerns, limits (or tolerance range) concerning maximum UF rate and 
sodium/conductivity range are also pre-specified (figure 2). Of note, there is no specific 
probe for plasmatic sodium with Hemocontrol®, as it is the case for Diacontrol® (see 
below). The dialysate conductivity is modulated toward a mean final value, but not in an 
automatic feedback response to patient’s plasmatic sodium. 
Overall, the goal of the Hemocontrol® system is to reach the same sodium and water 
balance as would a traditional approach, while the hemodynamic tolerability is enhanced by 
the profiling of the UF rate and the dialysate conductivity. Indeed, when the blood volume 
approaches the lower acceptable value for a given patient, UF is diminished or ceased while 
the dialysate conductivity is raised. Conversely, UF rate can be increased and/or dialysate 
conductivity decreased when blood volume is higher than expected on the pre-defined BV 
trajectory. 
5.2 BVM® Fresenius 
The Blood Volume Management (BVM®) module designed by Fresenius is available on the 
4008 and 5008 HD machines. This system also has relative blood volume as the core feature 
of the feedback loop, but rather deals with the « critical relative blood volume (cRBV) » 
concept instead of tracking an optimal curve to reach a final BV.   
The BV monitor is based on the measurement of total protein concentration (which includes 
plasma protein and Hb) by on-line ultrasound technology. Initially described by Schneditz 
(Schneditz et al., 1990), this method uses a probe in the arterial line that continuously 
measures the speed at which the ultrasounds travel through a specially designed cuvette. 
Since the sound speed is positively correlated to blood density, and, once again, assuming 
that the total content of blood does not change during UF, blood volume variations can be 
calculated from the changes in sound transmission velocity.  
The critical relative blood volume (cRBV) is individually determined for each patient. It is 
the threshold at which a particular patient would be at risk of IDH, based on the anterior 
sessions. The monitored parameter is the blood volume reduction, and a defined algorithm 
modulates the UF rate according to the relation of the actual BV to the cRBV. The algorithm 
is designed to allow the maximal UF rate at the beginning of the session, where the plasma 
refilling capacity is generally at its best, with a gradual decrease afterwards to avoid 
reaching the cRBV: 
 Actual UF rate = initial UF rate x factor        (1) 
 Initial UF rate = 2 x (remaining UF/remaining time)               (2) 
The actual UF rate is the delivered UF rate and the initial UF rate is two times the ratio 
between the remaining UF and the remaining time (remaining UF/remaining time). The 
factor is a coefficient between 0 and 1 determined according to the current RBV. When the 
cRBV is reached, the factor is 0 and so the UF is transitorily suspended until the RBV rises 
again. When the relative blood volume is more than halfway the distance between the cRBV 
and 100%, the factor is 1 and maximal UF is allowed.  Finally, when the RBV is more than 
halfway towards the cRBV, the factor is between 0 and 1 and decreases in a linear fashion 
(figure 3). This automatic feedback loop thus constantly adjust the UF rate to ensure, on one 
hand, that RBV stays over the predefined threshold and, on the other hand, that the UF rate 
is maximal at the beginning of the session and minimal at the end, where hypovolemia is  
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Fig. 3. BVM® algorithm (from Fresenius). 
This figure illustrates an example where the cRBV is set at 85%. When the actual RBV is 85% or 
less (white area), factor is 0 and UF stops. When RBV is greater than halfway between cRBV 
and 100% (here, halfway between 85% and 100% is 92,5%), the factor is 1,0 and UF is maximal 
(shaded area). In between (gray area), factor is between 0 and 1, and UF is not maximal. 
 
Fig. 4. UF rate in relation to RBV with the use of BVM® algorithm (from Fresenius). 
This figure illustrates the changes in UF rate (UFR) and RBV during HD given a cRBV 
set at 85% (same as Figure 3). The UFR is initially higher and progressively declines 
following reduction of RBV. 
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more likely to happen (figure 4). Of note, the dialysate conductivity is not an effector in this 
system and, unless a specific sodium profile is prescribed, remains unchanged. 
5.3 Impact of blood volume biofeedback systems 
The two biofeedback systems described above are designed differently but share the same 
goal: stabilizing blood volume reduction to avoid IDH and, ideally, its related 
complications. Many studies have been published on the ability of these devices to reduce 
vascular instability, mostly with the Hemocontrol® system, but few studies assessed other 
outcomes. Table 1 summarizes published trials that evaluated the impact of blood volume 
biofeedback systems. 
5.3.1 Reduction of intradialytic hypotension and nursing interventions 
Definition of IDH in the literature is not standardized and so differs between studies. Some 
authors use a strict definition based on an absolute or relative reduction of arterial pressure, 
while others report IDH as a drop in BP accompanied by symptoms and/or requiring 
nursing intervention (such as stopping or slowing UF, saline infusion or Trendelenburg’s 
position). Regardless of the definition used, the great majority of published trials, conclude 
that blood volume biofeedback systems are valuable in reducing IDH compared to standard 
hemodialysis (cf. table 1). Reduction of the proportion of HD sessions with at least one IDH 
episode ranges from 10 to 60%. However, it must be emphasized that most of these studies 
recruited patients who were already prone to hemodynamic instability, at varying degrees. 
As a general rule, the more severe and/or frequent the hemodynamic instability, the greater 
the benefits are from the automatic volume regulation. 
The largest randomized controlled trial assessing the impact of biofeedback regulation on IDH 
occurrence was published by Santoro in 2002. Thirty-two hypotension-prone patients recruited 
in ten Italian nephrology centers were analysed in a cross-over, parallel group study of 4 
months duration, comparing conventional HD to automatic BV-controlled HD. Although UF 
rate, pre and post-dialysis BP, and end-dialysis BV were the same with both treatments, a 30% 
reduction in dialysis sessions complicated by acute hypotension (systolic blood pressure ≤ 90 
mm Hg or a ≥ 25 mm Hg decrease with symptoms) was observed with the use of automatic 
biofeedback. An additional aim of this trial was to identify which patient’s parameters 
influence individual response to biofeedback. Clinical characteristics, dialysis prescriptions 
and plasma sodium values did not differ between the two treatment arms. However, two 
parameters appeared to be linked to responsiveness to BV-regulated feedback. First, good 
responders had higher final BV reduction and higher BV/UF ratio, suggesting a certain 
plasma refilling impairment. Second, poor responders had lower mean arterial pressure at the 
start of the HD sessions, and smaller increase in heart rate when standing from the lying 
position. Overall, these results indicate that IDH secondary to decreased plasma refilling 
capacity responds better to BV regulation than IDH due to impaired cardio-vascular reactivity. 
Of note, most studies that reported beneficial effects of biofeedback systems found similar 
results with regard to RBV changes during HD suggesting that reduction of IDH might not be 
exclusively explained by RBV preservation. As postulated by several authors, it is possible that 
treatment with BV automatic feedback exerts its favourable hemodynamic effect by preventing 
rapid RBV fluctuations (Santoro et al., 1994). 
To evaluate whether BP stabilisation obtained per-dialysis with Hemocontrol® in IDH-
prone patients was also sustained in the post-HD period, Franssen et al. (2005) used 24h BP 
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monitoring in a small prospective study. Following Hemocontrol®-driven HD, systolic 
blood pressure was significantly higher in the first 16 hours following HD, but this 
difference disappeared on the next morning. There was no difference in diastolic blood 
pressure. The authors concluded that the higher post HD systolic BP may explain the 
improvement of inter-HD symptoms observed in other studies (see below), although their 
study did not specifically evaluate interdialytic symptoms.  
Only one randomized controlled trial did not restrict patient selection on the basis of 
previous hemodynamic instability or fluid overload (Déziel et al. 2007). This study included 
57 patients (55% of them hypotension-prone) who were randomized to either standard HD 
or Hemocontrol®-driven HD. At 6 months, there was a 43% reduction in the number of 
sessions that required nursing interventions for IDH in the Hemocontrol® group (35% to 
19%), compared with a 36%  increase in nursing interventions  in the control group (23% to 
32%, p=0,04 for changes between groups). These results are in accordance with those 
reported by Ronco et al. (2000), who also demonstrated a significant decrease in the number 
of nursing interventions in a population prone to IDH when treated with BV biofeedback. 
Finally, two non-randomized, short-term prospective studies specifically assessed the value 
of BV-regulated HD among non hypotensive-prone patients (Wolkotte et al., 2002 and 
McIntyre et al., 2003). Both found a statistically significant improvement in dialysis tolerance 
in terms of reduction of IDH. 
 
Randomized trials       
       
Author Study 
design 
Patients Intervention 
(control) 
Duration Main 
endpoint(s) 
Results 
(treatment 
vs. control)     
Ronco 
(2000) 
RCT 
Cross-over 
12 patients
IDH-prone
AFB + HC 
vs. AFB 
4 weeks 
Sessions with 
IDH (%) 
33 vs. 82 p<0,001 
 
Equilibrated 
Kt/V 
1,13 vs. 
1,03 
p<0,001 
        
Santoro 
(2002) 
RCT 
Cross-over 
Multicenter
32 patients
IDH-prone
Std HD+HC 
vs. Std HD 
4 months 
Sessions with 
IDH (%) 
24 vs. 34 p=0,004 
 
Mean no. of 
interdialytic 
symptoms 
 
2,7 vs. 3,1 
 
p<0,001 
        
Moret 
(2006) 
RCT 
Cross-over 
10 patients
IDH-prone
Std HD+HC 
vs. Std HD 4 months 
Post-HD 
plasm. 
conduct. 
14,11 vs. 
14,11 
NS 
 
Ionic mass 
removal 
(mmol) 
432 vs. 383 NS 
     IDH (%) 16 vs. 8 NS 
        
Selby 
(2006) 
RCT 
Cross-over 
8 patients
IDH-prone
LVH 
Std HD+HC 
vs. Std HD 4 weeks 
No. of regional 
wall motion 
abnormalities
23 vs. 42 
OR 1,8; 
95%CI, 
1,1-3,0 
   
 No. of IDH 12 vs. 24 
OR 2,0; 
95%CI, 
1,0-4,4 
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Randomized trials       
Déziel 
(2007) 
RCT 57 patients 
Unselected
Std HD+HC 
vs. Std HD 
6 months Home SBP 
change (mm 
Hg) 
142 to 135 
vs. 
148 to 140 
NS 
between 
groups 
     Nursing 
interventions
(% change) 
-16 vs. +9 p=0,04 
     Kidney burden 
score 
(change in 
score) 
-6 vs. +5 p=0,004 
        
Dasselaar 
(2007) 
RCT 28 patients 
with 
hypertensi
on and 
volume 
overload 
Std HD+HC 
vs. Std HD 
16 weeks Pre-HD weight 
reduction (kg)
0,2 vs. 0,1 NS 
    Pre-HD SBP 
reduction 
(mm Hg) 
-23 vs. +3 p<0,01 
    Pre-HD DBP 
reduction 
(mm Hg) 
-8 vs. +1 p<0,05 
       
Garzoni 
(2007) 
RCT 
Cross-over 
Multi-center
56 patients 
IDH-prone
Std HD+BVM 
vs. Std HD 
6 weeks Sessions with 
IME requiring 
intervention 
(%) 
43 vs. 46 NS 
    Subgroup of 
high IDH 
incidence 
57 vs. 65 p=0,016 
        
Nesrallah 
(2008) 
RCT 60 patients 
with 
volume 
overload 
Std HD+BVM 
vs. Std HD 
6 months Change in 
ECFV (%) 
1,8 vs. 0,87 NS 
    Frequency of 
IDH 
0,11 vs. 
0,19 
p<0,01 
        
Gabrielli 
(2009) 
RCT 
Cross-over 
Multi-center
26 patients 
IDH-prone
Std HD+BVM 
vs. Std HD 
12 weeks Sessions with 
IME requiring 
intervention  
(%) 
32 vs. 40 p=0,02 
   
 
Mean no. of 
IME/session 
0,42 vs. 
0,53 
p=0,04 
    
 
Equilibrated 
Kt/V 
1,17 vs. 
1,12 
NS 
        
 
Non-randomized trials       
Santoro 
(1998) 
Prospective 
Cross-over 
8 
patients
IDH-
prone 
Std HD + HC 
vs. Std HD 
3 months
% of IDH 
26 vs. 44 
(A1) and 
27(A2) 
NS 
     
% of severe 
IDH 
3 vs. 27 
(A1) vs. 
17(A2) 
p<0,01 
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Non-randomized trials       
 
Basile 
(2001) 
 
Prospective 
Cross-over 
 
19 
patients 
IDH-
prone 
 
Std HD + HC 
vs. Std HD 
 
20 – 36 
months 
 
% sessions 
with IDH 
Post-HD 
asthenia score
21 vs. 32 
6,2 vs. 4,3 
p<0,0001 
p<0,0001 
        
Bégin 
(2002) 
Prospective 
Cross-over 
7 
patients
IDH-
prone 
Std HD + HC 
vs. Std HD 
12 weeks % of event-free 
sessions 
51 vs. 29 p<0,01 
 (sessions  
without 
intervention 
for IDH) 
  
        
Wolkotte 
(2002) 
Prospective 
Cross-over 
16 
patients 
Non 
IDH-
prone 
Std HD + HC 
vs. Std HD 
9 weeks 
% of IDH 
% of minor 
symptoms 
6 vs. 16 
11 vs. 18 
p<0,05 
p<0,05 
        
McIntyre 
(2003) 
Prospective 
Cross-over 
15 
patients 
Non 
IDH-
prone 
Std HD + HC 
vs. Std HD 
8 weeks 
% sessions 
with IDH 
3,5 vs. 7 p<0,001 
        
Franssen 
(2005) 
Prospective 12 
patients
Std HD + HC 12 weeks % sessions 
with IDH 
28 vs. 64 p<0,01 
 IDH-
prone 
vs. Std HD  Post-HD SBP o
24h recording
(mm Hg) 
Same at 
24h 
NS 
     Dry weight 
reduction (kg)
2,1 vs. 2,0 NS 
        
Winkler 
(2008) 
Observational 
Cohort 
18 
patients 
IDH-
prone 
with 
diabetes
Std HD + HC 
vs. baseline 
48 weeks No. of IDH per 
session 
Dry weight 
reduction (kg)
1 vs. 9 
-1,7 vs. 0 
p<0,01 
NS 
    % Cardiac 
ejection 
fraction 
53 vs. 43 NS 
        
 
Trials are subdivided in randomized or non-randomized studies and listed by year of publication. 
AFB: acetate-free biofiltration, BVM: blood volume monitor (Fresenius), DBP: diastolic blood 
pressure, ECVF: extracellular fluid volume, IDH: intradialytic, hypotension, IME: intradialytic morbid 
events, HC: Hemocontrol® (Gambro), HD: hemodialysis, LVH: left ventricular hypertrophy, NS: non-
significant, RCT: randomized controlled trial, SBP: systolic blood pressure, Std HD: standard 
bicarbonate-based hemodialysis 
 
Table 1. Trials on the use of blood volume biofeedback control system in chronic 
hemodialysis 
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5.3.2 Reduction of intra- and inter- dialytic symptoms and improvement in quality of 
life 
Regarding improvement of patient’s symptoms during HD, some data are available in the 
literature but they are mostly based on secondary outcome analysis and show only limited 
evidence of benefit. Basile et al. (2001) prospectively followed patients for up to 36 months 
with BV-regulated HD during which period nurses and patients had to fill a symptoms 
questionnaire for each HD session. A reduction of muscle cramps during HD and an 
improvement in the post-HD asthenia score were found to be significantly associated with 
biofeedback system. However, self-evaluation of other intra- and inter- HD symptoms 
(notably, thirst) was not significantly different between the two treatment arms. 
Ronco et al. (2000) found a significant reduction of the proportion of sessions with self-
reported intradialytic symptoms following treatment with BV-controlled UF (21% vs. 76%, 
p<0,001). In addition, Santoro et al. (2002) also showed a 10% decrease of interdialytic 
symptoms following treatment with BV-controlled HD.  
In a study by Déziel et al. (2007), the Kidney Disease and Quality of Life questionnaire 
(KDQOL) was used to evaluate quality of life at baseline and after 6 months of treatment 
with either Hemocontrol® or standard HD. Among the 20 items related to physical and 
mental health, only one parameter, burden of kidney disease, was significantly improved in 
the Hemocontrol® group versus the control group. Finally, in a randomized controlled trial 
of 60 patients, Nesrallah et al. (2008) did not find any significant difference with regard to 
dialysis-related symptoms and quality of life between the two treatment groups 
(Hemocontrol® versus standard HD) despite the fact that a reduction of IDH could be 
observed.   
5.3.3 Hypertension and volume control 
Three RCT specifically assessed the utility of BV regulation devices in improving fluid 
status and/or BP control in chronic hemodialysis patients. First, Dasselaar et al. (2007b) 
studied 12 hypertensive and mild volume-overloaded patients managed with either 
standard HD or BV tracking, where dry weight reduction was gradually undertaken by 
nephrologists according to clinical judgement. At 12 weeks, patients treated with BV 
regulation had a significantly lower pre- and post- HD systolic and diastolic blood pressure. 
Patients achieved larger UF volume without any change in RBV and showed reduction in 
extracellular water (determined by bioimpedance analysis). Despite these improvements in 
surrogate markers of volume status, no difference in mean weight from baseline could be 
observed. Authors concluded that this observation could result from increase in lean body 
mass; however, other specific nutritional parameters were not measured. 
Second, in a trial published by Nesrallah et al. in 2008, volume-overloaded patients were 
included if bioimpedance displayed an extracellular fluid volume (ECFV) of at least 45%.  In 
the treatment group, dry weight was adjusted by an algorithm guided by the Hemocontrol® 
biofeedback software based on plasma-refilling characteristics. At 6 months, there was no 
statistically significant difference between the two groups in the primary endpoint (change 
in ECFV) nor were there any significant differences in systolic blood pressure, total UF and 
interdialytic weight gain. 
Finally, in a trial by Déziel et al. (2007), change in home blood pressure was evaluated 
following treatment with BV device versus standard HD. Patients were not selected on the 
basis of prior hypertension or volume overload history. While the use of Hemocontrol® 
effectively reduced home systolic BP, the clinical-based decision algorithm to manage BP in 
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the standard group was as effective, and the overall difference between the groups was not 
significant.   
In summary, no randomized trial has clearly demonstrated that the use of biofeedback 
devices is superior to standard HD and clinical judgement in reducing dry weight in 
volume expanded patients. Biofeedback devices may be of value in reducing blood pressure 
in hypertensive patients, although a systematic and clinical treatment algorithm may be as 
useful.  
5.3.4 Reduction of left ventricular dysfunction 
Cardiovascular morbidity and mortality are extremely high among chronic HD patients. 
Aside from the conventional risk factors for atherosclerosis, it was proposed that recurrent 
subclinical myocardial ischemia occurring during HD, as a result of silent decrease in 
myocardial perfusion, may contribute to the excessive cardio-vascular burden. In support of 
this hypothesis, Selby et al. (2006) demonstrated that reversible regional wall motion 
abnormalities which develop in a majority of hypotension-prone patients during HD, were 
substantially reduced with biofeedback dialysis. However, the observation period in this 
study was only 4 weeks, and it is unknown at the present time whether biofeedback HD 
provides any benefit on long-term cardiac dysfunction.  
5.3.5 Improvement of dialysis delivery 
Hemodialysis and UF may cause vasoconstriction of peripheral vascular beds, thus 
reducing peripheral tissue perfusion.  This phenomenon may cause sequestration of urea, as 
only a central vascular loop of blood remains to be dialyzed. When hypotension occurs, this 
phenomenon may be aggravated leading to enhanced urea compartmentalization and 
reduced HD efficiency. Hence, it was proposed that improved hemodynamic stability 
during dialysis may improve urea removal and increase Kt/V. 
Ronco et al. (2000) conducted a multi-center, cross-over randomized trial of 12 IDH-prone 
patients treated for two weeks with acetate-free biofiltration (AFB, schedule A) and for two 
weeks with AFB plus Hemocontrol® (schedule B). Parameters of urea kinetics were 
significantly improved when patients were on schedule B, with higher equilibrated Kt/V (1,12 
vs. 1,03, p<0,001), and lower urea rebound at 30 minutes post-HD (6,4 vs. 14,2 g, p<0,001), 
despite similar predialysis urea concentration, HD prescriptions and treatment time. 
However, a larger randomized trial of 26 patients followed for 12 weeks and treated with 
standard HD or BVM-controlled HD in a cross-over fashion did not find any significant 
improvement of equilibrated Kt/V in the treatment group (1,17 vs. 1,12, p=0,156) in spite of 
a slightly but significant higher treatment time and a 20% reduction of intradialytic morbid 
events (Gabrielli et al., 2009). 
5.3.6 Morbidity and mortality 
With improved hemodynamic tolerance, reduction of left ventricular wall dysfunction, and 
superior dialysis delivery, it would be reasonable to assume that the use of biofeedback 
systems would improve morbidity and mortality in chronic dialysis patients. Unfortunately, 
no trial to date has examined this issue and the question remains open. 
Nevertheless, one large trial published in 2005 assessed the effect on morbidity of a BV-
monitor based algorithm of UF control versus conventional management of volemia. The 
CLIMB (Crit-Line® Intradialytic Monitoring Benefit) study (Reddan et al., 2005) was a 
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multi-centered, randomized, controlled trial of 443 chronic HD patients followed for 6 
months during which ultrafiltration was either managed according to Crit-Line® values of 
RBV reduction, or by usual clinical strategies. Patients were not selected on a basis of prior 
IDH history, and the algorithm of the treatment group was only proposed and not 
mandatory. During the follow-up period, there were no statistically significant differences 
between the two groups regarding the number of IDH, the occurrence of intradialytic 
symptoms and the control of BP. Surprisingly, the risk ratios for both non-access and access-
related hospitalizations were higher in the Crit-Line® group (adjusted RR 1,61 and 1,52; p-
value 0,01 and 0.04, respectively). Mortality was 8.7% in the treatment group and 3.3% in the 
control group (p=0.021). The authors concluded that the availability of Crit-Line® may alter 
clinicians’ behaviour and may cause a risk for patients, although these results have to be 
interpreted cautiously since the control group had an atypically low hospitalization and 
mortality rate.     
5.4 Blood volume biofeedback and sodium overload  
One of the potential risks of automated BV regulation using sodium (Na) or conductivity 
modulation is alteration in sodium removal, with consequent Na overload and increased 
thirst, which can theoretically lead to increased interdialytic weight gain and worsening 
hypertension. Most of the studies described above did not find a significant change in pre 
and post HD sodium concentration (Santoro et al., 2002; Wolkotte et al., 2002; Dasselaar et 
al., 2007b, etc.), although plasma Na is a poor surrogate of real sodium balance.  
Moret et al. (2006) assessed the effect of such devices on sodium transfer during 
hemodialysis. In a cross-over randomized trial of 10 patients with frequent hypotension, 
plasma conductivity (PC) and ionic mass balance (IMB) were compared in four different HD 
modalities: standard HD with fixed Na concentration (140 mmol/L), linear Na profiling (150 
to 140 mmol/L), BV-controlled feedback with Hemocontrol® (mean dialysate conductivity 
(DC) 14,0 mS/cm) and plasma-conductivity (PC)-controlled feedback with Diacontrol® (see 
below) (post-dialytic PC target of 14,0 mS/cm). Mean pre- and post-dialytic PC were 
statistically higher during Na-profiled HD, and post-dialytic PC was lower in PC-controlled 
feedback, compared to the other three modalities. The effects of BV-regulated HD on PC and 
IMB did not differ from those of standard HD, and thus it seems that BV-regulated HD can 
be prescribed without any safety concern regarding sodium loading.   
6. Other biofeedback systems 
Three other biofeedback systems were designed to reduce the occurrence of hypotensive 
episodes during HD. Rather than focusing on BV changes during HD, these devices use 
other targets (e.g. arterial BP) or other means of action  (e.g. thermal balance, plasma 
conductivity). They are reviewed here briefly. 
6.1 Arterial pressure biofeedback 
Arterial pressure biofeedback aimed at stabilizing BP during HD uses repetitive 
measurement of arterial blood pressure as the monitored parameter and a fuzzy-logic 
system as the controller of fluid removal. Created by B. Braun and implemented on the 
Dialog Advanced machines, the APBS® (Automatic Blood Pressure Stabilization system) 
puts blood pressure itself as the main input to the automatic fuzzy controller rather than a 
surrogate marker (e.g. blood volume). Fuzzy logic is a problem-solving system, rather than 
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a mathematical model, and is reported to be better suited to analyse and compute non-linear 
data systems. It mimics how a person would make a decision, based on judgments such as: « 
if X, then Y», according to the rules pre-set by the operator. In a practical manner, the 
operator has to set two parameters for each patient: the BP set point and the maximal UF 
rate. The set-point is the critical BP level at which the patient experiences symptomatic 
hypotension, or simply the BP threshold at which the nurse or the physician would consider 
stopping the UF in that particular patient. The maximal UF rate is defined as the maximal 
rate of fluid removal that can be applied at any time, since this system is designed to 
maximise UF rate at the start of the HD session and to minimize it towards the end. With a 
specialized arm cuff that takes BP measurements every five minutes, three variables are 
calculated (Mancini et al., 2007): 1) Relative difference between actual systolic BP and the 
pre-adjusted set point; 2) Short-term pressure trend (15 min); 3) Long-term pressure trend 
(25 min). These input data are then computed by the fuzzy controller through several steps 
that involve probabilistic reasoning according to specific rule bases, and ultimately result in 
modulation of the UF rate, in a closed feedback loop (figure 5). This system allows gradual 
and continuous variations of the UF rate, as it varies proportionally to the changes of the BP 
trends.  
 
 
Fig. 5. Fuzzy control of the UF rate. 
Technical scheme of the closed-loop system for the fuzzy control of the UF rate. (Adapted 
from Mancini et al., 2007) 
Literature on the use of fuzzy logic control in preventing IDH is still scarce, but a 
prospective multi-center study published in 2007 (Mancini et al., 2007) showed a significant 
decrease of 25% in IDH incidence in 55 hypotension-prone patients. The authors 
emphasized the need to introduce correct critical BP for each patient for the fuzzy controller 
to perform adequately (Mancini et al., 2007).    
6.2 Thermal balance system 
During HD, body temperature usually rises due in part to an increased production of heat 
secondary to inflammatory reactions induced by imperfect dialysate water and bio-
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compatibility of membranes, and in part by decreased blood flow to the skin, with 
subsequent heat retention. This phenomenon can contribute to hemodynamic instability. 
Cooler dialysate, by inducing vasoconstriction, is known to enhance vascular stability, but 
poor tolerance due to chills and discomfort is a major drawback to its use. 
Blood temperature control (BTC®, Fresenius) is a biofeedback system aimed at keeping 
body temperature stable throughout the session, with progressive decline of dialysate 
temperature in response to progressive increased in heat production, resulting in « 
isothermic dialysis » (Mercadal & Petitclerc, 2009). Designed by Fresenius, the blood 
temperature monitor (BTM) is composed of sensors in the arterial and venous lines and 
monitors blood temperature change by a thermodilution technique. Thermal balance can be 
maintained through the automatic modulation of the dialysate temperature (the output) by 
the BTC® software (the controller) in response to BTM measurements compared to the set 
target temperature (the input). 
A systematic review, published in 2006, reviewed the most pertinent publications on the 
clinical effects of cool dialysate (Selby & McIntyre, 2006). Six of them, which were all cross-
over studies of relatively short duration, evaluated the use of BTM compared to various 
control groups. Overall, there was a significant decrease in IDH frequency with reduction in 
dialysate temperature using BTM, with a rate of IDH 2.0 (95% CI, 1.9-2.1) times less than 
control group.  
6.3 Plasma conductivity biofeedback system  
This biofeedback system was designed to allow variation in the dialysate sodium (Na)  
concentration to better suit the patient’s initial plasmatic value and parallel the changes in 
plasma Na concentration occurring during dialysis. Instead of a fixed dialysate Na 
concentration, a target final plasma conductivity (as a surrogate for Na) is rather prescribed, 
and thus the patient’s post-dialysis sodium concentration is independent of the initial status. 
The goal of this system is to maximise sodium removal individually for each session, but 
avoiding large gap between plasmatic and dialysate sodium, which can produce patient’s 
discomfort, hypotension and cramps (if dialysate Na is lower) or sodium loading, thirst and 
worsening hypertension (if dialysate Na is higher).  
The Diascan® (Gambro) module monitors the patient’s plasma conductivity every 15 
minutes through conductivity probes located at the dialysate inlet and outlet. The software 
Diacontrol® (Gambro) computes this information and softly and gradually modulates the 
dialysate conductivity in order to reach the prespecified target plasmatic conductivity at the 
end of the session. The curve of the conductivity trajectory is pre-defined and minimizes 
large variations to avoid rapid shift of plasmatic osmolality and disequilibrium syndrome.  
Again, large randomized trials are lacking to evaluate the utility of this feedback system, 
and results of two small prospective studies published recently are conflicting. Both 
compared Diacontrol® to standard dialysis in stable patients to assess whether gradual 
decrease in target conductivity, and consequent increased ionic mass balance (meaning 
increased sodium removal) could be achieved. Manlucu and colleagues (2010) found a 
significant reduction in end plasmatic conductivity and in ionic mass balance, with 
consequent reduction in IDWG and BP. On the contrary, Selby and al. (2007) found a lower 
final conductivity with fixed dialysate conductivity, and no difference in BP, IDH frequency 
or dialysis tolerability. Hence, demonstration of a Diacontrol® beneficial effect remains to be 
proven. 
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8. Conclusions 
IDH is the most frequent complication of dialysis, and is associated with significant patient 
morbidity. Although pathogenesis is multifactorial, blood volume reduction appears to be 
central in the development of such events, especially when cardio-vascular compensatory 
mechanisms are impaired. In an attempt to reduce hypotensive episodes, blood volume 
biofeedback devices have been developed. The underlying premise of such devices is to 
automatically adjust dialysis parameters such as UF rate and dialysate conductivity, in 
response to variations of monitored patient’s characteristics, in order to make dialysis 
sessions more physiological and to prevent IDH by acting on subclinical signs of 
hemodynamic instability. Evidence supports BV biofeedback in hypotensive prone patients 
to reduce occurrence of IDH, nursing interventions, and probably intra- and inter- dialytic 
symptoms, although no large scale randomized trial has been published to date. BV 
biofeedback may also be helpful to enhance vascular tolerance in stable patients, but 
literature is limited. Data concerning improvement of hypertension and volume overload, as 
well as improvement of dialysis delivery, is conflicting. Finally, there is no large 
randomized trial that assessed the impact of automatic BV control on morbidity and 
mortality. Data suggesting that Crit-line® based algorithm of hypertension management is 
associated with higher hospitalisation and mortality rates are of concern. Larger and long-
term randomized trials comparing BV biofeedback devices to standard HD are needed to 
better define the impact of these novel technologies on patient outcomes. 
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